Journal article

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration

Laura Lores-Motta, Moeen Riaz, Michelle Grunin, Jordi Corominas, Freekje van Asten, Marc Pauper, Mathieu Leenders, Andrea J Richardson, Philipp Muether, Angela J Cree, Helen L Griffiths, Connie Pham, Marie-Claude Belanger, Magda A Meester-Smoor, Manir Ali, Iris M Heid, Lars G Fritsche, Usha Chakravarthy, Richard Gale, Martin McKibbin Show all



Importance: Visual acuity (VA) outcomes differ considerably among patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) drugs. Identification of pharmacogenetic associations may help clinicians understand the mechanisms underlying this variability as well as pave the way for personalized treatment in nAMD. Objective: To identify genetic factors associated with variability in the response to anti-VEGF therapy for patients with nAMD. Design, Setting, and Participants: In this multicenter genome-wide association study, 678 patients with nAMD with genome-wide genotyping data were included in the discovery phase; 1380 additio..

View full abstract